Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Phase 3CompletedNCT00195689

Abbott400 enrolled

Overview

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

400

Conditions

Psoriatic Arthritis

Interventions

Human anti-TNF monoclonal antibody/adalimumabBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject completed study M02-518 or M02-570 Exclusion Criteria: * Subject prematurely discontinued study M02-518 or M02-570 * Female subject who is pregnant or breast-feeding or considering becoming pregnant * Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

Locations (1)

Global Medical Information-Abbott Laboratories

Abbott Park, Illinois, United States

Outcomes

Primary Outcomes

Safety parameters

ACR 20/50/70

PsARC

HAQ

SF-36

FACTIT Fatigue Scale

Disease progression measurements

Secondary Outcomes

Patient reported outcomes

Clinical response indicators

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.